Trials / Recruiting
RecruitingNCT05735639
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) - a Multi-centre Assessor-blind Randomised-controlled Trial
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 6,660 (estimated)
- Sponsor
- Imperial College London · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself. Varicose veins are enlarged veins close to the surface of the skin. They are connected to the bigger deeper veins in the leg (known as deep veins). Because of this, operations to close the varicose veins can increase the chance of a blood clot forming in the deep veins. Blood clots in the deep veins happen in around 1 in 50 people after endovenous operations. A clot in the leg can cause swelling, pain, and other long-term problems. If a clot in the leg breaks off and travels to the lungs, it can cause problems with the lung' ability to move oxygen from the air into the blood and may, in rare cases, be life threatening. Varicose vein procedures may carry a slightly higher risk of blood clot formation, and we are currently unsure if current clot reducing medicines are beneficial in preventing blood clots in people having varicose vein procedures. This study will investigate if it is worthwhile prescribing medicines to reduce blood clots after varicose vein procedures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dalteparin Sodium | Low molecular weight heparin |
| DRUG | Tinzaparin Sodium | Low molecular weight heparin |
| DRUG | Enoxaparin Sodium | Low molecular weight heparin |
| DRUG | Rivaroxaban | Direct oral anticoagulant |
| DRUG | Apixaban | Direct oral anticoagulant |
| DRUG | Dabigatran Etexilate | Direct oral anticoagulant |
Timeline
- Start date
- 2024-01-22
- Primary completion
- 2026-06-30
- Completion
- 2026-12-31
- First posted
- 2023-02-21
- Last updated
- 2025-05-02
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05735639. Inclusion in this directory is not an endorsement.